AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
ANIDULAFUNGIN
6 registrations across 3 African markets— 6 active
Markets with ANIDULAFUNGIN
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| ECALTA POWDER INJECTION | 🇬🇭Ghana | — | active | Mar 2030 |
| ECALTA POWDER INJECTION | 🇬🇭Ghana | — | active | Mar 2030 |
| ANIDULAFUNGIN 100 mg ACCORD | 🇿🇦South Africa | Accord Healthcare (Pty) Ltd | active | Apr 2029 |
| ECALTA Powder And Solution For Solution For Injectio | 🇰🇪Kenya | PFIZER LABORATORIES LIMITED | active | Aug 2027 |
| ERAXIS 100 mg | 🇿🇦South Africa | Pfizer Laboratories (Pty) Ltd | active | Jan 1900 |
| ARANDI 100 mg | 🇿🇦South Africa | Sandoz South Africa (Pty) Ltd | active | Jan 1900 |
ANIDULAFUNGIN in Africa — Regulatory Overview
ANIDULAFUNGIN is registered across 3 African markets with 6 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Ghana, Kenya. AfricaRegulatory refreshes this data daily from official government sources.
Of the 6 registrations, 6 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.